Browse > Article

Characteristics and Quality of Life in Patients with Chemotherapy-Induced Peripheral Neuropathy  

Kwak, Mi-Kyong (Department of Nursing, Samsung Medical Center)
Kim, Eun-Ji (Department of Nursing, Samsung Medical Center)
Lee, Eun-Ryung (Department of Nursing, Samsung Medical Center)
Kwon, In-Gak (Department of Clinical Nursing Science, Sunkyunkwan University School of Medicine)
Hwang, Moon-Sook (Department of Clinical Nursing Science, Sunkyunkwan University School of Medicine)
Publication Information
Asian Oncology Nursing / v.10, no.2, 2010 , pp. 231-239 More about this Journal
Abstract
Purpose: The purpose of study was to identify how patients experienced chemotherapy-induced peripheral neuropathy (CIPN) and quality of life related to CIPN. Methods: This was a descriptive research. We collected data from 105 patients with chemotherapy-induced peripheral neuropathy. They completed a self-reported questionnaire including Eastern Cooperative Oncology Group (EORTC) CIPN20 and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment. Results: In the study, duration of peripheral neuropathy was 9.4 month and 54.3% of patients used pharmacological or non-pharmacological interventions. Patients reported the highest score for sensory scale and it's score was $38.74{\pm}20.24$. The scores for motor scale and autonomic scale were $21.95{\pm}19.19$ and $26.61{\pm}21.0$ respectively. This showed that patients more suffered from sensory neuropathy than any other domain of neuropathy. The most frequently selected two items were 'did you have tingling fingers or hands?' and 'did you have tingling toes or feet?'. Conclusion: The results of this study will provide useful information for chemotherapy-induced peripheral neuropathy.
Keywords
Chemotherapy; Peripheral neuropathy; Quality of life;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sweeney CW. Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clin J Oncol Nurs 2002;6:163-6.   DOI   ScienceOn
2 Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 2007;23:162-73.   DOI   ScienceOn
3 Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135-9.   DOI   ScienceOn
4 Backonja M, Beydoun A, Edwards KR. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280: 1831-6.   DOI   ScienceOn
5 Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: A randomized clinical trial. Arch Phys Med Rehabil 1995;76:612-20.   DOI   ScienceOn
6 Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J the Peripher Nerv Syst 2008;13:27-46.   DOI   ScienceOn
7 Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006; 10:279-87.   DOI   ScienceOn
8 Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M et al. NCCN task force report: Management of neuropathy in cancer. J Natl Compr Canc Netw 2009;7:S1-S26.
9 Richardson J, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 2001;82:205-9.   DOI   ScienceOn
10 Diana Donavan. Management of peripheral neuropathy caused by microtubule inhibitor. Clin J Oncol Nurs 2009;13:686-94.   DOI   ScienceOn
11 Rao RD, Michalak JC, Sloan JA. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double blind, placebo-controlled, crossover trial. Cancer 2007;110:2110-8   DOI   ScienceOn
12 Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2007;35:31-9.
13 Balducci S, Lacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complicat 2006;20:216-23.   DOI   ScienceOn
14 Campbell A. Subjective measures of well-being. Am Psychol 1976;31:117-24.   DOI
15 Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.   DOI   ScienceOn
16 Smith EL, Whedon MK, Bookbinder M. Quality improvement of painful peripheral neuropathy. Semin Oncol Nurs 2002;18: 36-43.   DOI   ScienceOn
17 Wickhan R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs 2007;11:361-76   DOI   ScienceOn
18 Boehmke MM & Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs 2005;28:382-9.   DOI   ScienceOn
19 Postma TJ, Heimans JJ. Grading of chemotherapy induced peripheral neuropathy. Annals of Oncology 2000;11:509-13.   DOI   ScienceOn
20 Katsumasa Kuroi, Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, et al. A questionnaire survey of physicians' perspective regarding the assessment of chemotheraphy-induced peripheral neuropathy in patients with Breast cancer. Jpn J Clin Oncol 2008;38:748-54.   DOI   ScienceOn
21 Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care in Cancer, Online first at http://www.springerlink.com/content/e958243151613358/;2009.
22 Ellen ML, Susan LB, Jeffrey C. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2008;35:96-102.   DOI   ScienceOn
23 Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2005; 32:305-11.   DOI   ScienceOn
24 Wilkes GM. Neurologic disturbances. Cancer symptom management. Boston: Jones and Bartlett;1999.